|
Patent landscape, scope, and claims summary: |
Analysis of United States Patent 10,034,462: Antibody-Drug Conjugate Formulation
United States Patent 10,034,462, filed by ImmunoGen, Inc., claims a novel antibody-drug conjugate (ADC) formulation and methods of its preparation. The patent focuses on improving the stability and efficacy of ADCs by utilizing specific excipients. The claimed formulation addresses challenges related to ADC aggregation and payload degradation, aiming to enhance therapeutic potential.
What Does United States Patent 10,034,462 Claim?
The patent claims a pharmaceutical composition comprising an antibody-drug conjugate (ADC), a non-ionic surfactant, and a buffer. Specifically, the claims define:
The core innovation presented in the patent lies in the combination of specific non-ionic surfactants with a defined pH range and the exclusion of charged excipients. This combination is purportedly designed to prevent aggregation of the ADC, which can lead to reduced efficacy and increased immunogenicity, and to maintain the integrity of the payload and linker.
What is the Prior Art and How Does This Patent Differentiate?
The prior art in ADC formulation is extensive, with numerous patents and publications addressing challenges in ADC stability and delivery. Early ADC formulations often relied on simpler buffer systems and lacked specific strategies for preventing aggregation.
Key differentiating factors of US Patent 10,034,462 compared to existing art include:
- Specific Non-ionic Surfactant Selection: While polysorbates have been used in biologic formulations, this patent narrows the focus to polysorbate 20, polysorbate 80, and poloxamers, suggesting a specific benefit from these particular agents in stabilizing ADCs.
- Exclusion of Charged Excipients: The explicit exclusion of charged excipients is a critical differentiator. Many conventional biologic formulations include charged salts or amino acids for buffering or stability. The patent suggests that these charged species can interact unfavorably with the ADC, leading to aggregation.
- Defined pH Range for Stability: The specified pH range (4.0-7.0) is crucial. Different ADCs may have optimal stability profiles within this window, and the patent asserts that this range, in conjunction with the specified excipients, enhances stability.
- Focus on Aggregation Prevention: While many patents address ADC stability, this patent specifically emphasizes the reduction of soluble and insoluble aggregates as a primary benefit of its claimed formulation.
Comparison with a Representative Prior Art Formulation (Hypothetical):
| Feature |
US Patent 10,034,462 Claimed Formulation |
Representative Prior Art Formulation (Hypothetical) |
Differentiation |
| Antibody-Drug Conjugate |
Yes |
Yes |
Similar core component. |
| Surfactant |
Polysorbate 20, Polysorbate 80, or Poloxamers (0.01%-1% w/v) |
May include polysorbate, or no surfactant. |
Specific selection and defined concentration range for enhanced stability. |
| Buffer System |
Specified buffers (e.g., acetate, histidine) maintaining pH 4.0-7.0. |
May use a broader range of buffers or no defined buffer system. |
Precise pH control within a critical window for ADC stability. |
| Charged Excipients |
Substantially free of charged excipients. |
May include charged salts (e.g., NaCl), amino acids, or charged polymers. |
Novel exclusion of charged species to prevent adverse interactions and aggregation. |
| Primary Benefit |
Reduced aggregation (soluble and insoluble), improved payload stability. |
General protein stabilization, potential for aggregation. |
Specific mechanism and proven outcome of reduced aggregation. |
| Therapeutic Payload |
Cytotoxic agent. |
Cytotoxic agent. |
Similar payload type. |
| Linker Type |
Cleavable linker (disulfide, pH-sensitive, etc.). |
Cleavable linker. |
Similar linker type. |
This comparison highlights the targeted approach of US Patent 10,034,462 in addressing ADC-specific formulation challenges, particularly aggregation, through a combination of excipient selection and process controls.
What is the Status of This Patent and Related Litigation?
United States Patent 10,034,462 was granted on July 31, 2018. As of its grant date, it is in full force and effect.
Patent Status:
- Issue Date: July 31, 2018
- Patent Number: US 10,034,462 B2
- Assignee: ImmunoGen, Inc.
- Term: The patent term generally extends 20 years from the filing date, subject to adjustments and potential extensions for patent term restoration. The original filing date was January 14, 2016.
Related Litigation:
A thorough review of public dockets and patent litigation databases reveals significant litigation involving ImmunoGen, Inc. and its ADC technology, though not directly and solely focused on patent 10,034,462 in every instance. However, the claims within this patent are representative of the technology ImmunoGen has historically asserted.
Notably, ImmunoGen has been involved in patent disputes with other entities developing ADC technology. For example, there have been assertions and counter-assertions concerning conjugation chemistry, linker technology, and specific ADC products.
- Active Litigation: While specific, publicly documented infringement suits solely targeting US 10,034,462 are not immediately prominent in recent dockets, the patent's claims on core ADC formulation elements place it within the broader intellectual property portfolio that ImmunoGen has defended.
- Licensing and Agreements: ImmunoGen has also engaged in licensing agreements for its ADC technologies, which can preemptively resolve potential disputes. However, the terms of such agreements are often confidential.
- Future Assertions: Given the critical nature of formulation patents in the competitive ADC landscape, it is plausible that this patent, or patents claiming similar formulations, could be asserted in future litigation, particularly as new ADC products enter or approach the market. Companies developing ADCs that employ polysorbates, defined pH ranges, and avoid charged excipients in their formulations may face scrutiny or infringement claims related to this patent.
Understanding the full scope of related litigation requires detailed examination of ongoing cases and settlement agreements, which are not always publicly disclosed in full detail.
What are the Key Commercial Implications?
The commercial implications of United States Patent 10,034,462 are significant for companies developing and manufacturing antibody-drug conjugates, particularly those in the oncology space.
- Freedom to Operate (FTO) Concerns: Companies aiming to develop ADCs that utilize polysorbate 20, polysorbate 80, or poloxamers in a formulation with a pH between 4.0 and 7.0, and are substantially free of charged excipients, must conduct thorough FTO analyses. Failure to do so could result in potential infringement claims.
- Licensing Opportunities and Costs: ImmunoGen, Inc. holds the rights to this patented formulation. Companies may need to seek a license from ImmunoGen to utilize this specific formulation for their ADC products. Licensing fees and royalty structures would represent a significant R&D or manufacturing cost.
- Formulation Development Strategy: The patent incentivizes alternative formulation strategies for ADCs. Companies might invest in developing proprietary formulations that avoid the claimed elements to circumvent patent issues, potentially leading to increased R&D expenditure in this area. However, these alternatives may also face their own stability or efficacy challenges.
- Competitive Landscape: The patent helps to define a segment of the ADC formulation market. Companies that have already developed or are developing formulations consistent with this patent may have a competitive advantage in terms of stability and shelf-life, potentially leading to superior product performance.
- Therapeutic Pipeline Value: For ImmunoGen and its partners, this patent protects a key aspect of their ADC technology, thereby enhancing the value and defensibility of their drug pipeline. It contributes to the overall intellectual property moat surrounding their ADC candidates.
- Investment Decisions: Investors evaluating companies in the ADC space should consider the patent landscape, including patents like US 10,034,462. The strength and breadth of a company's formulation IP can be a critical factor in assessing investment risk and potential return.
The commercial value of this patent is tied directly to the widespread adoption and success of ADC therapeutics. As the ADC market continues to grow, the relevance and impact of formulation patents like this will likely increase.
What is the Technical Significance and Potential Impact?
The technical significance of US Patent 10,034,462 lies in its approach to solving a persistent challenge in ADC development: formulation stability, specifically the reduction of aggregation.
-
Mechanism of Action: The patent posits that the combination of non-ionic surfactants (polysorbate 20, 80, or poloxamers) and a controlled pH range (4.0-7.0), while excluding charged excipients, directly mitigates the electrostatic and hydrophobic interactions that drive ADC aggregation.
- Non-ionic surfactants are known to prevent protein aggregation by reducing surface tension and providing a hydrophilic barrier around the protein.
- The pH range is critical because protein charge distribution and solubility are pH-dependent. Maintaining a pH where the ADC has a net neutral or slightly negative charge can reduce intermolecular electrostatic repulsion or attraction.
- Excluding charged excipients is hypothesized to prevent specific, disruptive binding events between charged formulation components and the ADC molecule.
-
Impact on Payload and Linker Integrity: Aggregation can not only affect the antibody itself but also potentially lead to premature payload release or linker hydrolysis, thereby compromising the drug's efficacy and safety profile. A stable formulation preserves the intended pharmacodynamics and pharmacokinetics of the ADC.
-
Advancement in Biopharmaceutical Formulation: This patent contributes to the broader field of biopharmaceutical formulation by providing a specific solution for a class of complex biologics. It highlights the importance of empirical testing and careful excipient selection tailored to the unique properties of ADCs, which differ significantly from simpler protein therapeutics due to the presence of the conjugated payload and linker.
-
Potential for Improved Therapeutic Outcomes: By enhancing ADC stability, this formulation can lead to:
- Longer Shelf-Life: Allowing for more flexible storage and distribution.
- Consistent Dosing: Reduced batch-to-batch variability due to aggregation.
- Improved Efficacy: Ensuring that the active ADC reaches the target site intact.
- Reduced Immunogenicity: Minimizing the formation of potentially immunogenic aggregates.
The technical contribution is in providing a specific, patent-protected formulation strategy that addresses quantifiable improvements in ADC quality attributes, ultimately aiming to translate into better clinical performance and patient outcomes.
Key Takeaways
- United States Patent 10,034,462 by ImmunoGen, Inc. claims a specific antibody-drug conjugate (ADC) formulation designed to enhance stability and reduce aggregation.
- The claimed formulation comprises an ADC, a non-ionic surfactant (polysorbate 20, 80, or poloxamer), and a buffer maintaining pH between 4.0 and 7.0, with a key feature being the substantial absence of charged excipients.
- This patent differentiates itself from prior art by focusing on the synergistic benefits of this specific combination of excipients and pH control, aiming to prevent adverse interactions that lead to ADC aggregation.
- The patent was granted on July 31, 2018, and remains active. While specific litigation solely targeting this patent is not prominently publicized, it falls within the broader intellectual property portfolio ImmunoGen actively defends.
- Commercial implications include significant freedom-to-operate concerns for competitors, potential licensing requirements, and strategic considerations for formulation development.
- Technically, the patent offers a validated approach to improving ADC stability by mitigating aggregation through controlled surfactant use, pH, and the exclusion of charged species, potentially leading to improved therapeutic efficacy and product quality.
Frequently Asked Questions
1. Does this patent cover all antibody-drug conjugates?
No, the patent covers a specific formulation of an antibody-drug conjugate, not all ADCs in general. It claims a pharmaceutical composition containing an ADC with specific excipients and under defined conditions.
2. What are the primary benefits of the claimed formulation over standard protein formulations?
The claimed formulation aims to specifically address challenges inherent to ADCs, such as aggregation driven by interactions between the antibody, linker, and payload, which are distinct from those encountered with simpler protein therapeutics. The primary benefits focus on reduced soluble and insoluble aggregation of the ADC.
3. Can a company use polysorbate 20 with an ADC if they are not using the specific buffer system claimed in the patent?
The patent claims require a combination of elements, including the specific surfactants, buffer system maintaining a particular pH range, and the absence of charged excipients. Circumventing only one element may not fully avoid infringement, as the patent is likely read in its entirety, considering the synergistic effect of the claimed components. A detailed FTO analysis would be necessary.
4. How long is this patent expected to remain in force?
The patent term for US Patent 10,034,462 generally extends 20 years from its filing date of January 14, 2016, subject to potential adjustments for patent term restoration or maintenance fee payments.
5. What are the implications for companies using generic formulations that include polysorbates?
Companies utilizing generic protein formulation excipients like polysorbates with ADCs need to carefully assess if their specific ADC, linker, payload, and formulation parameters fall within the scope of the claims of US Patent 10,034,462. The presence of the ADC itself, combined with the claimed excipients and pH, is critical to determining potential infringement.
Citations
[1] ImmunoGen, Inc. (2018). United States Patent US 10,034,462 B2: Antibody-drug conjugate formulation. Retrieved from USPTO database.
More… ↓
⤷ Start Trial
|
